将国际循证指南适配本地挑战:黎巴嫩视角解读最新ATS/IDSA社区获得性肺炎抗菌治疗推荐
该专家小组综述评估黎巴嫩近期国家抗菌药物耐药(AMR)数据,审阅2019年ATS/IDSA社区获得性肺炎(CAP)指南及其2025年更新,将多数推荐保留、并依据本地耐药模式调整关键病原体的经验性抗菌药物选择。提出的管理流程按疾病严重程度、诊疗场所和AMR风险对患者分层,并将病原体特异性危险因素纳入临床决策,以期优化目标治疗、支持抗菌药物管理与保全抗生素有效性。
要点
- 依据本地AMR数据调整CAP经验性抗菌药物选择,而非照搬国际推荐。
- 管理流程按病情严重程度、诊疗场所与AMR风险分层。
- 将病原体特异性危险因素整合进临床决策以支持抗菌药物管理。
核心结论
- 在黎巴嫩耐药上升背景下,将ATS/IDSA的CAP抗菌治疗推荐结合本地AMR数据加以适配,以优化目标治疗并保全抗生素有效性。
研究设计与样本
- 专家小组综述:评估黎巴嫩近期国家AMR数据,审阅2019年ATS/IDSA CAP指南及其2025年更新,据此提出本地化推荐与管理流程。
主要发现
- 多数ATS/IDSA推荐被保留,但依据本地耐药模式对关键病原体的经验性抗菌药物选择进行了调整。
- 提出的管理算法按疾病严重程度、诊疗场所和AMR风险对患者分层,并整合病原体特异性危险因素。
临床怎么用
- 临床可依据病情严重程度、诊疗场所与AMR风险分层选择经验性抗菌治疗,并结合病原体特异性危险因素调整方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
J Glob Antimicrob Resist. 2026 Jan;46:98-108. doi: 10.1016/j.jgar.2025.11.005. Epub 2025 Nov 17. ABSTRACT Community-acquired pneumonia (CAP) remains a major global health concern, particularly in regions with rising antimicrobial resistance (AMR). In Lebanon, increasing resistance among respiratory pathogens complicates management, limiting treatment options and worsening clinical and economic outcomes. This expert panel review assessed recent national AMR data to adapt CAP treatment recommendations to the Lebanese context. The 2019 ATS/IDSA guidelines and their 2025 update were reviewed; while most recommendations were retained, empiric antibiotic choices were adjusted for key pathogens based on local resistance patterns. The proposed management algorithm stratifies patients by disease severity, care setting, and AMR risk, integrating pathogen-specific risk factors into clinical decisions. By contextualizing international guidance to local epidemiology and healthcare infrastructure, these recommendations aim to optimize targeted therapy, support antimicrobial stewardship, and preserve antibiotic efficacy in Lebanon's evolving resistance landscape. PMID: 41260518 | DOI: 10.1016/j.jgar.2025.11.005
引用
- 指南共识 · 肺炎:Adapting international evidence-based guidelines to local challenges: A Lebanese perspective on the latest American Thoracic Society and Infectious Diseases Society of America (ATS/IDSA) community-acquired pneumonia antibacterial therapy recommendations
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。